This website uses cookies to ensure you get the best experience on our website. Learn more
Got it!
Oct 29, 2020
Exvastat is pleased to announce the CounterCOVID trial of oral imatinib in Severe COVID-19 infection has reached the milestone of 50% recruitment into the 386-patient study.
The full details of the study protocol can be found here:
May 15, 2020